Varian, a subsidiary of Siemens Healthineers, has rolled out Isolis cryoprobe, a single use device intended for use with its CryoCare systems, to improve cryoablation procedures.
Cryoablation is a minimally invasive, image-guided procedure that involves freezing to destroy targets such as tumors of the lung, liver, breast, kidney, prostate, and soft tissue.
CryoCare systems are used in the general surgery, urology, gynecology, oncology, neurology, dermatology, ENT, proctology, pulmonary surgery, and thoracic surgery procedures.
The systems are designed to apply extreme cold temperatures to ablate prostate and kidney tissue, liver metastases, tumours, skin lesions, and warts.
Varian said that its new Isolis cryoprobe will provide the interventional radiologist with enhanced operational control, to enhance predictability, precision, and efficiency.
The disposable device features a small 2.1mm/14-gauge shaft and a sharp probe tip to enable smooth and accurate placement.
Also, Isolis the first cryoprobe compatible for optional integration with the Siemens Healthineers myNeedle Laser guidance system for image-guided interventional procedures.
Clinician can use myNeedle Laser to guide the insertion and trajectory of the cryoprobe while using imaging to monitor placement progress, said Varian.
Varian interventional solutions president Francis Facchini said: “The Isolis cryoprobe reflects the significant opportunity Varian has as a Siemens Healthineers company to seek to raise the standards of procedural efficiency and precision.
“This exciting development represents the first new interventional radiology product since combining with Siemens Healthineers, and a first step towards our goal of making these impactful, minimally invasive treatment options easier to execute and more widely accessible to the patients who can benefit.
“We look forward to further collaboration and innovation on behalf of patients worldwide, as we continue to advance our mission to help create a world without fear of cancer.”
Varian, engaged in providing cancer care technologies and solutions, along with interventional solutions and software solutions, was acquired by Siemens in 2021.
Last year, Siemens Healthineers and Varian jointly teamed up with University of Miami Health System (UHealth), to advance the medical equipment at the health system.
Earlie this year, Varian has received both US Food and Drug Administration (FDA) and CE mark approvals for its Halcyon and Ethos radiotherapy systems featuring its HyperSight technology.
